Promising cancer combo trial halted after just 2 patients

NCT ID NCT06939036

Terminated Disease control Sponsor: Ariceum Therapeutics GmbH Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminated early after enrolling only 2 participants, so no meaningful results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 225Ac-SSO110 (a radioactive drug) plus standard immune checkpoint inhibitors
What this could lead to: If it had worked, this could have pointed toward a new treatment option for people with advanced lung or skin cancer.
What could go wrong: The trial was terminated early with only 2 participants enrolled, so no conclusions can be drawn. The approach is very early-stage and may not be safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MERKEL CELL CARCINOMA SMALL CELL LUNG CANCER EXTENSIVE STAGE

Contacts and locations

Locations

Biogenix Molecular

Miami, Florida, 33165, United States
GenesisCare

Alexandria, Australia
John Theurer Cancer Center at Hackensack UMC

Hackensack, New Jersey, 07601, United States
UPMC

Pittsburgh, Pennsylvania, 15219, United States
United Theranostics

Glen Burnie, Maryland, 21061, United States
University of Louisville Health-Brown Cancer Center

Louisville, Kentucky, 40202, United States
Virginia Cancer Specialists, PC

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.